Investigation of the effectiveness of Buspirone and Mirtazapine on functional dyspepsia

Phase 2

• Conditions: Functional dyspepsia.; Functional dyspepsia,Mirtazapine,Buspirone,Anxiety

• Registration Number: IRCT20210724051972N1
• Lead Sponsor: Birjand University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Willingness to participate in the study after explaining all the objectives of the research and the advantages and disadvantages of the methods
Failure to receive psychological treatment before entering the study
Lack of other structural or functional gastrointestinal disorders
No other organic disease
Possibility to keep the type and amount of drug used during the research period if the drug is used
No alcohol and drugs
No psychotic disorder and personality disorder
Absence of alarm signs such as gastrointestinal bleeding, blood in the stool, fever, weight loss, anemia, nocturnal diarrhea, severe heartburn
Age between 18 and 50 years

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The severity of dyspepsia symptoms in the three groups receiving buspirone, mirtazapine and the control group. Timepoint: The severity of dyspepsia symptoms in the three groups receiving buspirone, mirtazapine before the intervention and one month after the intervention and three months after the intervention and in the control group before the intervention and one month after the intervention. Method of measurement: patient assessment of upper gastrointestinal symptom severity index questionnaire(pagi-sym).;Beck anxiety score in three groups receiving buspirone, mirtazapine and control group. Timepoint: Determining and comparing the mean score of Beck anxiety in the two groups receiving buspirone, receiving mirtazapine before the intervention, one month after the intervention and three months after the intervention and in the control group before the intervention and one month after the intervention. Method of measurement: Beck Anxiety Questionnaire.